Does menopausal hormone therapy reduce myocardial infarction risk if initiated early after menopause? A population-based case-control study

Menopause

Volumn 22, Issue 6, 2015, Pages 598-606

  Carrasquilla, German D ^a   Berglund, Anita ^a   Gigante, Bruna ^a   Landgren, Britt Marie ^a   De Faire, Ulf ^a,b   Hallqvist, Johan ^c   Leander, Karin ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Biological markers; Cardiovascular diseases; Epidemiology; Menopausal hormone therapy; Menopause; Myocardial infarction

Indexed keywords

ESTROGEN DERIVATIVE; ESTROGEN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MIDDLE AGED; POPULATION RESEARCH; RISK ASSESSMENT; TIME TO TREATMENT; TREATMENT DURATION; ESTROGEN THERAPY; HEALTH STATUS; MYOCARDIAL INFARCTION; ODDS RATIO; PROCEDURES; SECONDARY PREVENTION; SWEDEN; WOMEN'S HEALTH;

ADULT; CASE-CONTROL STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HEALTH STATUS; HUMANS; MENOPAUSE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; SECONDARY PREVENTION; SWEDEN; WOMEN'S HEALTH;

EID: 84930470427     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000354     Document Type: Article

References (53)

1. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75: 1102-1109.
2. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-762.
3. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-461.
4. Heckbert SR, Weiss NS, Koepsell TD, et al. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. Arch Intern Med 1997;157:1330-1336.
5. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
7. Clarkson TB, Melendez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause 2013;20:342-353.
8. Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal womenVresults from 2 large clinical trials. Arch Intern Med 2004;164:482-484.
9. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21:363-366.
10. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-365.
11. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591-2602.
12. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011; 305:1305-1314.
13. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409.
14. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15:35-44.
15. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.
16. Hernan MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology 2008;19:766-779.
17. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009;170:12-23.
18. Chilvers CE, Knibb RC, Armstrong SJ, Woods KL, Logan RF. Post menopausal hormone replacement therapy and risk of acute myocardial infarctionVa case control study of women in the East Midlands, UK. Eur Heart J 2003;24:2197-2205.
19. Toh S, Hernandez-Diaz S, Logan R, Rossouw JE, Hernan MA. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear A randomized trial. Ann Intern Med 2010;152:211-217.
20. Koh KK, Yoon BK. Controversies regarding hormone therapy: insights from inflammation and hemostasis. Cardiovasc Res 2006;70:22-30.
21. Bingol B, Gunenc Z, Yilmaz M, Biri A, Tiras B, Guner H. Effects of hormone replacement therapy on glucose and lipid profiles and on cardiovascular risk parameters in postmenopausal women. Arch Gynecol Obstet 2010;281:857-864.
22. Terauchi M, Honjo H, Mizunuma H, Aso T. Effects of oral estradiol and levonorgestrel on cardiovascular risk markers in postmenopausal women. Arch Gynecol Obstet 2012;285:1647-1656.
23. Howard BV, Rossouw JE. Estrogens and cardiovascular disease risk revisited: the Women's Health Initiative. Curr Opin Lipidol 2013;24:493-499.
24. ACOG Committee Opinion No. 565: hormone therapy and heart disease. Obstet Gynecol 2013;121:1407-1410.
25. Moyer VA. Menopausal hormone therapy for the primary prevention of chronic conditions: US Preventive Services Task Force recommendation statement. Ann Intern Med 2013;158:47-54.
26. The North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257-271.
27. Reuterwall C, Hallqvist J, Ahlbom A, et al. Higher relative, but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the SHEEP study. The SHEEP Study Group. J Intern Med 1999;246:161-174.
28. Behandlingsprogram för Danderyds sjukhus, Ersta sjukhus, Huddinge sjukhus, Karolinska sjukhuset, Löwenströmska sjukhuset, Nacka sjukhus, Norrtälje sjukhus, Sabbatsbergs sjukhus, S. t Görans sjukhus, Södersjukhuset, Södertälje sjukhus. Cardiac intensive care (in Swedish). Stockholm, Sweden: Stockholm County Council; 1990.
29. Moller J, Hallqvist J, Diderichsen F, Theorell T, Reuterwall C, Ahlbom A. Do episodes of anger trigger myocardial infarction A case-crossover analysis in the Stockholm Heart Epidemiology Program (SHEEP). Psychosom Med 1999;61:842-849.
30. Nordenhem A, Leander K, Hallqvist J, de Faire U, Sten-Linder M, Wiman B. The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project. Thromb Res 2005; 116:223-232.
31. The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14:355-369.
32. Labrie F, Cusan L, Gomez JL, et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009;16:30-36.
33. Leander K, Hallqvist J, Reuterwall C, Ahlbom A, de Faire U. Family history of coronary heart disease, a strong risk factor for myocardial infarction interacting with other cardiovascular risk factors: results from the Stockholm Heart Epidemiology Program (SHEEP). Epidemiology 2001; 12:215-221.
34. Romelsjo A, Branting M, Hallqvist J, et al. Abstention, alcohol use and risk of myocardial infarction in men and women taking account of social support and working conditions: the SHEEP case-control study. Addiction 2003;98:1453-1462.
35. Mannila MN, Eriksson P, Leander K, et al. The association between fibrinogen haplotypes and myocardial infarction in men is partly mediated through pleiotropic effects on the serum IL-6 concentration. J Intern Med 2007;261:138-147.
36. Banks E, Canfell K. Invited Commentary: Hormone therapy risks and benefitsVthe Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. Am J Epidemiol 2009;170:24-28.
37. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-941.
38. Zegura B, Guzic-Salobir B, Sebestjen M, Keber I. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause 2006;13:643-650.
39. Cooper BC, Burger NZ, TothMJ, CushmanM, Sites CK. Insulin resistance with hormone replacement therapy: associations with markers of inflammation and adiposity. Am J Obstet Gynecol 2007;196:123.e1-123.e7.
40. Koh KK. Effects of hormone replacement therapy on coagulation and fibrinolysis in postmenopausal women. Int J Hematol 2002;76:44-46.
41. Gokkusu C, Ozbek Z, Tata G. Hormone replacement therapy: relation to homocysteine and prooxidant-antioxidant status in healthy postmenopausal women. Arch Gynecol Obstet 2012;285:733-739.
42. Gol M, Akan P, Dogan E, Karas C, Saygili U, Posaci C. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas 2006;53:252-259.
43. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273-284.
44. Greenland S, Thomas DC. On the need for the rare disease assumption in case-control studies. Am J Epidemiol 1982;116:547-553.
45. Research on the menopause in the 1990s. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1996;866:1-107.
46. Danaei G, Tavakkoli M, Hernan MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol 2012;175:250-262.
47. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
48. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95:s1-s66.
49. Jain MG, Rohan TE, Howe GR. Agreement of self-reported use of menopausal hormone replacement therapy with physician reports. Epidemiology 1999;10:260-263.
50. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999;149:981-983.
51. Rossouw JE. Postmenopausal hormone therapy for disease prevention: have we learned any lessons from the past. Clin Pharmacol Ther 2008; 83:14-16.
52. Shlipak MG, Angeja BG, Go AS, Frederick PD, Canto JG, Grady D. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation 2001;104:2300-2304.
53. Hamsten A, Walldius G, Dahlen G, Johansson B, De Faire U. Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction. Atherosclerosis 1986;59:223-235.